TECHSTARS
14.9.2021 10:02:34 CEST | Business Wire | Press release
Techstars , the worldwide network that helps entrepreneurs succeed, announces the launch of two new accelerator programs in Paris and Stockholm. The launch showcases Techstars’ commitment to investing in startup talent in Europe, where it plans to invest in more than 100 startups in 2022 through its various accelerator programs in seven countries. Both programs will be fully funded by Techstars, following the recent July close of a new $150 million fund , intended to support more local entrepreneurs looking for global exposure.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210914005314/en/
The Paris Techstars Accelerator and Stockholm Techstars Accelerator will each accept 12 startups per class, who will benefit from up to $120k in funding alongside evergreen access to Techstars’ vast network of mentors, investors, alumni and corporate partners. The Paris accelerator will operate two classes per year, while Stockholm will run once in 2022 and twice per year from 2023 onwards. Applications for these accelerators open today and will close on 1 December 2021, with the first classes of both programs due to commence on 21 March 2022.
Applications will be accepted from startups across all high-growth sectors, both B2B and B2C, and successful applicants will have a strong founding team who are using technology to tackle complex problems, with a clear and scalable product-market fit.
The Paris and Stockholm Techstars Accelerator programs follow the recent appointment of French-born CEO, Maëlle Gavet, in January 2021. An experienced French entrepreneur and former executive at Compass and Booking.com, Gavet’s experience scaling companies across Europe will assist Techstars on its mission to help more entrepreneurs in more places transform the world through access to capital and a global network.
Techstars currently operates 47 accelerators in 33 cities and 12 countries around the world, and while it previously operated a Paris-based accelerator in partnership with corporate partners, the Stockholm Techstars Accelerator marks its first venture into Sweden as it eyes expansion opportunities across Europe. Since 2009 and 2010, the company has been actively supporting thousands of entrepreneurs in Paris and Stockholm, respectively, by hosting more than 90 Techstars Startup Weekend programs in both cities, in close collaboration with local ecosystem leaders. Additionally in Europe, Techstars operates programs in London, Amsterdam, Berlin, Oslo and Turin.
Since its inception in 2006, Techstars has invested in 2,589 companies, which today have a combined market capital valuation of $220.1 billion. It counts 15 unicorns among its accelerator graduates, including DigitalOcean, Chainalysis, PillPack and SendGrid. Techstars invests in approximately 500 startups and deploys approximately $130M per year, making it one of the largest investors in high-growth early-stage companies by volume in the world.
Maëlle Gavet, CEO of Techstars , said: “We believe in the power of local ecosystems and that life-changing ideas can come from anywhere in the world - you don’t need to be in Silicon Valley to be a success. At Techstars, we meet the founders where they are and use our local networks to give them access to world-class capital and investing opportunities they wouldn’t otherwise have. Paris and Stockholm are two of Europe’s most rapidly growing yet underserved tech hubs, and we know there is a huge amount of talent there ready to be harnessed.”
Applications to apply to the Paris Techstars Accelerator and Stockholm Techstars Accelerator are open now.
About Techstars
The Techstars worldwide network helps entrepreneurs succeed. Founded in 2006, Techstars began with three simple ideas—entrepreneurs create a better future for everyone, collaboration drives innovation, and great ideas can come from anywhere. Now we are on a mission to enable every person on the planet to contribute to, and benefit from, the success of entrepreneurs. In addition to operating accelerator programs and venture capital funds, we do this by connecting startups, investors, corporations, and cities to help build thriving startup communities. Techstars has invested in more than 2,589 companies with a combined market cap of more than $220.1B. www.techstars.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210914005314/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
U.S. FDA Grants Priority Review to BeOne Medicines’ BRUKINSA Combination in First-Line Mantle Cell Lymphoma4.11.2026 15:13:00 CET | Press release
If approved, BRUKINSA plus rituximab would be the first and only chemotherapy-free, BTK inhibitor-based regimen for adult patients with previously untreated mantle cell lymphomaApplication supported by Phase 3 MANGROVE data, showing a 43% reduction in the risk of progression or death versus bendamustine plus rituximabFull MANGROVE results to be presented during the Plenary Scientific Session at the 68th American Society of Hematology Annual Meeting BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE study, in which this chemotherapy-free regimen significantly reduced the risk of dis
Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement4.11.2026 15:00:00 CET | Press release
This framework agreement provides all entities subject to the French Public Procurement Code with simplified access to a support alternative enabling them to control their costs, preserve their freedom of technological choice and free themselves from vendor-imposed upgrade cycles Rimini Street, Inc. (Nasdaq: RMNI), the Software Support and Agentic AI ERP Company™ and the leading third-party support provider for Oracle, SAP and VMware software, today announced that it had been selected as the awardee of the third-party support service lots (TMA) by CANUT, the French public purchasing center specializing in digital technology and telecommunications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104431817/en/ Rimini Street Awarded CANUT Third-Party Maintenance Framework Agreement Eligible public organizations subject to the French Public Procurement Code can now benefit from Rimini Street services for their Oracle, SAP, VMw
Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 20264.11.2026 15:00:00 CET | Press release
New data in myeloproliferative neoplasms (MPNs) will include INCA033989, Incyte’s first-in-class, mutant calreticulin (mutCALR)-targeted monoclonal antibody, in first-line myelofibrosis (MF); and preclinical findings for Incyte’s next-generation mutCALR- and JAK2V617F-targeted compoundsUpdated results for INCA033989 in second-line MF and second-line essential thrombocythemia (ET) will build on previously presented datasetsLong-term Phase 1/2 data further characterize the potential of latarcibart (VGA039), an investigational Protein S-targeting antibody, as prophylaxis in adolescents and adults with von Willebrand disease (VWD)More than 30 abstracts will highlight progress across Incyte’s broader hematology portfolioIncyte will host an investor event and webcast on Saturday, December 12, 2026 from 7:30 – 9:00 p.m. CT (8:30 – 10:00 p.m. ET) Incyte (Nasdaq:INCY) today announced that new data highlighting progress across its hematology portfolio will be presented across more than 30 abstra
Zenitar Announces Initiation of International Randomized Study of Flonoltinib Maleate in Patients with Myelofibrosis and Related American Society of Hematology 2026 Meeting Presentations4.11.2026 15:00:00 CET | Press release
Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and TSS50 with FM 50/100mg versus ruxolitinib; previous data presented orally at ASH24 (#486) and ASH25 (#908). ASH 2026 presence covers FMF-02 long-term follow-up (oral presentation, #411, December 12, 4:30pm) and refractory PV Phase 2 data (poster, #3765, December 13, 6pm), both in Session 634. “Over the 15 years since the initial FDA approval of Ruxolitinib, JAKi have markedly improved the prognosis of many patients with MF. The long-term data show significant room for improvement for this key therapeutic class in terms of both e
Trained Therapeutix Discovery Appoints Andrew Glass as Chief Executive Officer4.11.2026 14:41:00 CET | Press release
Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years in senior leadership roles at Abbott. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261104178009/en/ Andrew Glass, CEO, TTxD Following the previously announced changes to the Company’s Board earlier this year, Mr. Glass joins the Company as it transitions from preclinical stage to being a clinical-stage organisation. His expertise in developmental strategy, financing and organisational growth is focussed on expediting the delivery of the aims associated with TTxD’s proprietary
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
